[U: Added Lilly To Graphic!] Amgen Spent 54% Less Than Amazon And/Or Pfizer In Q1 2023 -- Lobbying To Bend A Passel Of Laws, In Its Favor...

This will close out this quarter's series. However, though -- just for fun, I might add Lilly into this group, at some point next week.

We will see how busy the day job gets. Here's the run-down -- but taxes, patent evergreening and provisions to make drugs and other therapies and treatments more affordable. . . top the list of items we are watching most closely:

. . .Issues related to drug pricing reform; Changes to Public law 117-1769 Inflation Reduction Act; Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act; S. 113 Prescription Pricing for the People Act of 2023; S.127 Pharmacy Benefit Transparency Act; HR 830 HELP Copays Act; HR 485 Protecting Health Care for All Patients Act; HR 1613 to amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program issues related to cardiovascular disease awareness and treatment; Issues related to Federal Trade Commission; FDA issues; Issues related to clinical trial diversity; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Biosimilars reimbursement issues, no specific bill; Supply Chain Issues, no specific bill; Issues related to 340B (PROTECT 340B act of 2023); Issues related to pharmacy benefits managers. . . .

Issues related to drug pricing reform; Changes to Public law 117-1769 Inflation Reduction Act; Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act; S. 113 Prescription Pricing for the People Act of 2023; S.127 Pharmacy Benefit Transparency Act; HR 485 Protecting Health Care for All Patients Act; HR 1613 To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program issues related to cardiovascular disease awareness and treatment; Issues related to ESRD; Issues related to asthma and self-administered drug list; Issues related to reimbursement for biologics/biosimilars. . . .

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income. . . .

S. 79 Interagency Patent Coordination and Improvement Act of 2023; S. 113 Prescription Pricing for the People Act of 2023; S.127 Pharmacy Benefit Transparency Act; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop STALLING Act; S. 142 Preserve Access to Affordable Generics and Biosimilars; Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to march-in/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to false claims act; Issues related to FDA/PTO coordination; Issues related to patent thickets/product hopping. . . .

Now you know -- out into the sunshine -- grinning. . . .

नमस्ते